Business Context and Reporting Period
This Form 8-K filing by Aveanna Healthcare Holdings, Inc. (AVAH) reports a corporate event occurring on October 21, 2025, with the report dated October 23, 2025. The filing details the completion of a secondary offering of common stock by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of a secondary equity offering.
- Shares Sold: 10,000,000 shares of common stock.
- Offering Price: $9.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.
- Company Proceeds: $0. The Company did not issue or sell any shares and received no proceeds from this transaction.
Material Changes
The material change reported is the execution and closing of a secondary offering by existing shareholders. This transaction results in a change in the ownership structure of the company but does not alter the Company's capital structure or cash position as no new shares were issued by the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose specific risks or contingencies beyond the standard incorporation by reference of the Underwriting Agreement. The transaction was underwritten by Jefferies LLC and J.P. Morgan Securities LLC.
Investor Verification Checklist
- Verify the total number of shares outstanding post-offering to assess potential dilution impact on existing shareholders.
- Confirm the identity and remaining holdings of the Selling Stockholders (affiliated with J.H. Whitney Equity Partners VII, LLC) to understand future selling pressure.
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up provisions or other restrictions on the selling stockholders.
- Check subsequent filings to determine if the 1,500,000 share over-allotment option was exercised.